Announcement

Date

Time

Subject

2024/06/14

15:57:27

Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, Medeon International, Inc.

SEQ_NO	3	Date of announcement	2024/06/14	Time of announcement	15:57:27
Subject	Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, Medeon International, Inc.
Date of events	2024/06/14	To which item it meets	paragraph 11
Statement	1.Date of the board of directors resolution:2024/06/14 2.Source of capital increase funds: Issuance of common shares for cash capital increase 3.Whether to adopt shelf registration (Yes, please state issuance period/No):N/A 4.Total monetary value of the issuance and number of shares issued (shares issued not including those distributed to employees if consisting in capital increase from earnings or capital surplus): Total monetary value of the issuance?GUS$4,000,040 Number of shares issued?G4,000,040 shares 5.If adopting shelf registration, monetary value and number of shares to be issued this time:N/A 6.The remaining monetary value and shares after this issuance when adopting shelf registration:N/A 7.Par value per share:US$1 8.Issue price:US$1 9.Number of shares subscribed for by or allocated to employees:N/A 10.Number of shares publicly sold:N/A 11.Ratio of shares subscribed by or allotted as stock dividends to existing shareholders:100% 12.Handling method for fractional shares and shares unsubscripted for by the deadline:N/A 13.Rights and obligations of these newly issued shares: The rights and obligations of the newly issued shares from this cash capital increase are the same as those of existing shares. 14.Utilization of the funds from the capital increase: To invest in subsidiary 15.Any other matters that need to be specified:None

2024/06/14

15:50:34

Medeon Board of Directors resolved the appointments for the 5th session of Remuneration Committee

SEQ_NO	2	Date of announcement	2024/06/14	Time of announcement	15:50:34
Subject	Medeon Board of Directors resolved the appointments for the 5th session of Remuneration Committee
Date of events	2024/06/14	To which item it meets	paragraph 6
Statement	1.Date of occurrence of the change:2024/06/14 2.Name of the functional committees:Compensation committee 3.Name of the previous position holder: Chi Hang Yang Chia Ying Ma Jerome Shen 4.Resume of the previous position holder: Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation 5.Name of the new position holder: Chi Hang Yang Chia Ying Ma Jien Wei Yeh Feng Shyang Yang 6.Resume of the new position holder: Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jien Wei Yeh?GChair Professor, Department of Material Science Engineering, National Tsing Hua University Feng Shyang Yang?GSupervisor, Adimmune Corporation 7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’, ‘term expired’, ‘death’ or ‘new appointment’):Term expired 8.Reason for the change:Term expired 9.Original term (from __________ to __________):2021/07/16~2024/07/15 10.Effective date of the new member:2024/06/14 11.Any other matters that need to be specified:None

2024/06/14

15:43:10

BOD of Medeon re-elected Mr. Yue Teh Jang as the Chairman.

SEQ_NO	1	Date of announcement	2024/06/14	Time of announcement	15:43:10
Subject	BOD of Medeon re-elected Mr. Yue Teh Jang as the Chairman.
Date of events	2024/06/14	To which item it meets	paragraph 6
Statement	1.Date of the board of directors resolution or date of occurrence of the change:2024/06/14 2.Position (Please enter chairperson or president/general manager):Chairman 3.Name of the previous position holder:Yue Teh Jang 4.Resume of the previous position holder:Chairman, Medeon Biodesign, Inc. 5.Name of the new position holder:Yue Teh Jang 6.Resume of the new position holder:Chairman, Medeon Biodesign, Inc. 7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’, ‘term expired’ , ‘job relocation’, ‘severance’, ‘retirement’, ‘death’ or ‘new appointment’):Term expired 8.Reason for the change:Term expired and re-elected 9.Effective date of the new appointment: 2024/06/14 10.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None

2024/06/12

17:20:14

Announcement for the term expiration of the Company’s Remuneration Committee

SEQ_NO	5	Date of announcement	2024/06/12	Time of announcement	17:20:14
Subject	Announcement for the term expiration of the Company's Remuneration Committee
Date of events	2024/06/12	To which item it meets	paragraph 6
Statement	1.Date of occurrence of the change:2024/06/12 2.Name of the functional committees:Remuneration Committee 3.Name of the previous position holder: Chi Hang Yang Chia Ying Ma Jerome Shen 4.Resume of the previous position holder: Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation 5.Name of the new position holder:Not appointed yet 6.Resume of the new position holder:Not appointed yet 7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’, ‘term expired’, ‘death’ or ‘new appointment’):Term expired 8.Reason for the change:Term expired 9.Original term (from __________ to __________):2021/07/16~2024/07/15 10.Effective date of the new member:Not appointed yet 11.Any other matters that need to be specified: The new Remuneration Committee will be announced upon appointment by the Board of Directors.

2024/06/12

15:20:01

Announcement for the Members of 4th session of Audit Committee

SEQ_NO	4	Date of announcement	2024/06/12	Time of announcement	15:20:01
Subject	Announcement for the Members of 4th session of Audit Committee
Date of events	2024/06/12	To which item it meets	paragraph 6
Statement	1.Date of occurrence of the change:2024/06/12 2.Name of the functional committees:Audit Committee 3.Name of the previous position holder: Chi Hang Yang Chia Ying Ma Jerome Shen Jien Wei Yeh 4.Resume of the previous position holder: Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation Jien Wei Yeh?GChair Professor, Department of Material Science Engineering, National Tsing Hua University 5.Name of the new position holder: Chi Hang Yang Chia Ying Ma Jien Wei Yeh Feng Shyang Yang 6.Resume of the new position holder: Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jien Wei Yeh?GChair Professor, Department of Material Science Engineering, National Tsing Hua University Feng Shyang Yang?GSupervisor, Adimmune Corporation 7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’, ‘term expired’, ‘death’ or ‘new appointment’):Term expired 8.Reason for the change:Term expired 9.Original term (from __________ to __________):2021/07/16~2024/07/15 10.Effective date of the new member:2024/06/12 11.Any other matters that need to be specified:None

2024/06/12

15:13:50

Medeon approved to release newly elected Directors or representatives from Non-Competition Restrictions at the Annual Shareholders’ Meeting

SEQ_NO	3	Date of announcement	2024/06/12	Time of announcement	15:13:50
Subject	Medeon approved to release newly elected Directors or representatives from Non-Competition Restrictions at the Annual Shareholders' Meeting
Date of events	2024/06/12	To which item it meets	paragraph 21
Statement	1.Date of the shareholders’ meeting resolution:2024/06/12 2.Name and title of the managerial officer with permission to engage in competitive conduct: CENTER LABORATORIES INC. ; Director Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu; Director Legal Representative of Medeon, Inc., Yue Teh Jang; Director Chi Hang Yang; Independent Director Chia Ying Ma; Independent Director Jien Wei Yeh; Independent Director 3.Items of competitive conduct in which the officer is permitted to engage: Invest in or manage other companies with the same or similar scope of business as Medeon Biodesign, Inc. 4.Period of permission to engage in the competitive conduct: During the period of serving as director of Medeon Biodesign, Inc. 5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): Shares represented at the time of voting: 52,090,101 rights Number of voting rights of shareholders present at the time of voting Votes in favor 51,633,784 votes?APercentage of the total represented share present 99.12% Votes against 166,110 votes?APercentage of the total represented share present 0.31% Votes invalid 0 votes?APercentage of the total represented share present 0.00% Votes abstained 290,207 votes?APercentage of the total represented share present 0.55% 6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter ‘N/A’ below): Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director 7.Company name of the mainland China enterprise and the officer’s position in the enterprise: Director, Beijing Shundu Pharmaceutical Research Institute Co., Ltd. Director, Shanghai Bio Pharmaceuticals Co., Ltd. Director, Scindy Pharmaceutical (SuZhou), Ltd. 8.Address of the mainland China enterprise: Beijing Shundu Pharmaceutical Research Institute Co., Ltd.?GRoom 904, 9th Floor, No. 61, West Balizhuang Li, Chaoyang District, Beijing Shanghai Bao Pharmaceuticals Co., Ltd?GNo. 28 Luoxin Road, Baoshan District, Shanghai Scindy Pharmaceutical (Suzhou) Co., Ltd.?GAddress: 6 / F, Block B, Building 4, No. 108 Yuxin Road, Suzhou Industrial Park, Suzhou, Jiangsu, P.R.China 9.Operations of the mainland China enterprise: Beijing Shundu Pharmaceutical Research Institute Co., Ltd.?G Biotechnology Services Shanghai Bio Pharmaceuticals Co., Ltd.?G Development of Recombinant Protein Drugs and Antibody Drugs Scindy Pharmaceutical (SuZhou), Ltd.?G Medical Research and Trial Development 10.Impact on the company’s finance and business:N/A 11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:N/A 12.Any other matters that need to be specified:None

2024/06/12

15:05:56

Announcement of re-election of Directors at the 2024 Annual Shareholders’ Meeting and the change of more than one-third of Directors

SEQ_NO	2	Date of announcement	2024/06/12	Time of announcement	15:05:56
Subject	Announcement of re-election of Directors at the 2024 Annual Shareholders' Meeting and the change of more than one-third of Directors
Date of events	2024/06/12	To which item it meets	paragraph 6
Statement	1.Date of occurrence of the change:2024/06/12 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): institutional director, independent director 3.Title and name of the previous position holder: Director – Legal Representative of Medeon, Inc. Yue Teh Jang Director – Legal Representative of CENTER LABORATORIES INC. Jung Chin Lin Director – Legal Representative of CENTER LABORATORIES INC. Chih Hsiung Wu Director – Hong Jen Chang Director – Hsin Yuan Fang Independent Director – Chi Hang Yang Independent Director – Chia Ying Ma Independent Director – Jerome Shen Independent Director – Jien Wei Yeh 4.Resume of the previous position holder: Legal Representative of Medeon, Inc., Yue Teh Jang?GGM of Medeon Biodesign, Inc. Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin?GDirector of BioGend Therapeutics Co.,Ltd. Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu?GChairman of V-CHECK, INC. Hong Jen Chang?G Chairman and CEO, YFY Biotech Management Company Hsin Yuan Fang?GVice Superintendent of Department of Surgery, China Medical University Hospital Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation Jien Wei Yeh?GChair Professor, Department of Material Science Engineering, National Tsing Hua University 5.Title and name of the new position holder: Director – Legal Representative of Medeon, Inc., Yue Teh Jang Director – Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin Director – Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu Independent Director – Chi Hang Yang Independent Director – Chia Ying Ma Independent Director – Jien Wei Yeh Independent Director – Feng Shyang Yang 6.Resume of the new position holder: Legal Representative of Medeon, Inc., Yue Teh Jang?GGM of Medeon Biodesign, Inc. Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin?GDirector of BioGend Therapeutics Co.,Ltd. Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu?GChairman of V-CHECK, INC. Chi Hang Yang?GChairman, SVT Investment Co. , Ltd Chia Ying Ma?GProfessor, Department of Accounting , Soochow University Jien Wei Yeh?GChair Professor, Department of Material Science Engineering, National Tsing Hua University Feng Shyang Yang?GSupervisor, Adimmune Corporation 7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’, ‘term expired’, ‘death’ or ‘new appointment’):term expired 8.Reason for the change: Term expired and re-elected Directors 9.Number of shares held by the new position holder when elected: Director – Legal Representative of Medeon, Inc. Yue Teh Jang; 10,450,911 shares Director – Legal Representative of CENTER LABORATORIES INC. Jung Chin Lin; 27,411,028 shares Director – Legal Representative of CENTER LABORATORIES INC. Chih Hsiung Wu; 27,411,028 shares Independent Director – Chi Hang Yang; 0 shares Independent Director – Chia Ying Ma; 0 shares Independent Director – Jien Wei Yeh; 0 shares Independent Director – Feng Shyang Yang; 0 shares 10.Original term (from __________ to __________):2021/07/16~2024/07/15 11.Effective date of the new appointment:2024/06/12 12.Turnover rate of directors of the same term:NA 13.Turnover rate of independent directors of the same term:NA 14.Turnover rate of supervisors of the same term:NA 15.Change in one-third or more of directors (Please enter ‘Yes’ or ‘No’):Yes 16.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None

2024/06/12

14:51:51

Announcement for the material resolutions at the 2024 Annual Shareholders’ Meeting.

SEQ_NO	1	Date of announcement	2024/06/12	Time of announcement	14:51:51
Subject	Announcement for the material resolutions at the 2024 Annual Shareholders’ Meeting.
Date of events	2024/06/12	To which item it meets	paragraph 18
Statement	1.Date of the shareholders’ meeting:2024/06/12 2.Important resolutions I.Profit distribution/deficit compensation: Ratification of 2023 deficit offset proposal 3.Important resolutions II.Amendments of the company charter:None 4.Important resolutions III.Business report and financial statements: Ratification of 2023 Business Report and Financial Statements 5.Important resolutions IV.Election for directors and supervisors: Completion of the Election for the 6th session of Directors. 6.Important resolutions V.Other matters: (1) Approval of the proposal for the private placement to issue additional common shares (2) Approval of the release of newly elected directors or its representatives from Non-Competition Restrictions. 7.Any other matters that need to be specified:None

2024/06/07

16:38:27

Medeon is invited to attend the investor conference held by MasterLink Securities

SEQ_NO	1	Date of announcement	2024/06/07	Time of announcement	16:38:27
Subject	Medeon is invited to attend the investor conference held by MasterLink Securities
Date of events	2024/06/12	To which item it meets	paragraph 12
Statement	1.Date of institutional investor conference:2024/06/12 2.Time of institutional investor conference:14:30 3.Location of institutional investor conference: 11F., No. 97, Sec. 2, Dunhua S. Rd., Taipei City (Tunnan Tower, 11F., Education and Training Room in MasterLink Securities) 4.Outline of institutional investor conference: The Company is invited to attend the investor conference held by MasterLink Securities to outline an overview of the Company’s current operational status and future development plans. 5.Any other matters that need to be specified:None

2024/05/24

15:40:10

BOD of Medeon’s major subsidiary Medeologix re-elected Mr. Yue Teh Jang as the Chairman.

SEQ_NO	6	Date of announcement	2024/05/24	Time of announcement	15:40:10
Subject	BOD of Medeon’s major subsidiary Medeologix re-elected Mr. Yue Teh Jang as the Chairman.
Date of events	2024/05/24	To which item it meets	paragraph 6
Statement	1.Date of the board of directors resolution or date of occurrence of the change:2024/05/24 2.Position (Please enter chairperson or president/general manager): Chairperson 3.Name of the previous position holder:Yue Teh Jang 4.Resume of the previous position holder:Chairman, Medeologix Corporation 5.Name of the new position holder:Yue Teh Jang 6.Resume of the new position holder:Chairman, Medeologix Corporation 7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’, ‘term expired’ , ‘job relocation’, ‘severance’, ‘retirement’, ‘death’ or ‘new appointment’):Term expired 8.Reason for the change:Term expired and re-elected 9.Effective date of the new appointment:2024/05/24 10.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None